Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | TTR | P02766 | 2/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 3/20 | 0.35 |
| ▸ | NECTIN4 | Q96NY8 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21781738 | 1.00 | CYP3A4 (0.50) | CYP3A4FOLH1TTRSSTR2AKT1 | |
| SCHEMBL21781915 | 1.00 | CYP3A4 (0.50) | CYP3A4FOLH1TTRSSTR2AKT1 | |
| SCHEMBL22068460 | 0.99 | CYP3A4 (0.51) | CYP3A4FOLH1TTRSSTR2AKT1 | |
| SCHEMBL22068559 | 0.99 | CYP3A4 (0.51) | CYP3A4FOLH1TTRSSTR2AKT1 | |
| SCHEMBL21781809 | 0.97 | CYP3A4 (0.52) | CYP3A4FOLH1TTRSSTR2AKT1 | |
| SCHEMBL22068555 | 0.96 | CYP3A4 (0.52) | CYP3A4FOLH1TTRSSTR2AKT1 | |
| SCHEMBL22068551 | 0.96 | CYP3A4 (0.52) | CYP3A4FOLH1TTRSSTR2AKT1 | |
| SCHEMBL22068554 | 0.96 | CYP3A4 (0.52) | CYP3A4FOLH1TTRSSTR2AKT1 | |
| SCHEMBL21781977 | 0.95 | CYP3A4 (0.47) | CYP3A4FOLH1TTRSSTR2AKT1 | |
| SCHEMBL21781918 | 0.95 | CYP3A4 (0.50) | CYP3A4FOLH1TTRSSTR2AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11207420-B2 | Cytotoxin and conjugate, uses of same and preparation method therefor | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-12-28 | — | — | US | disclosed |
| US-20200179529-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME AND PREPARATION METHOD THEREFOR | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-06-11 | — | — | US | disclosed |
| EP-3617221-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME, AND PREPARATION METHOD THEREFOR | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207420-B2 | Cytotoxin and conjugate, uses of same and preparation method therefor | CD2, HAVCR2, CD4 | CYP3A4 949/4885FOLH1 1690/4885TTR 558/4885 |
| US-20200179529-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME AND PREPARATION METHOD THEREFOR | CD2, HAVCR2, CD4 | CYP3A4 949/4885FOLH1 1690/4885TTR 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.